Altamira Therapeutics LTD F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
F-1/A: Altamira Therapeutics Seeks Up to $5 Million in Public Offering to Advance RNA Delivery Platforms
Altamira Therapeutics is offering up to 5,952,380 common shares, pre-funded warrants, and associated warrants in a public offering to fund working capital and general corporate purposes.
Altamira Therapeutics plans to offer up to 5,952,380 common shares, pre-funded warrants, and associated warrants in a public offering.
Altamira Therapeutics is planning a public offering of common shares, pre-funded warrants, and accompanying warrants to raise capital for working capital and general corporate purposes.
F-1: Altamira Therapeutics Seeks to Register 2 Million Common Shares for Resale by Lincoln Park Capital
Altamira Therapeutics has filed a registration statement for the resale of up to 2,000,000 common shares by Lincoln Park Capital Fund, LLC.